Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Will R&D Suffer When Pfizer, Allergan Merge?

This article was originally published in Scrip

Executive Summary

Reducing Pfizer Inc.'s tax rate is undeniably the top reason for the company's pending $160bn merger with Allergan PLC, but without pharmaceutical products and research programs that could significantly boost revenue growth, it seems unlikely that Pfizer would invest billions of dollars and invoke the ire of US politicians and regulators by completing a tax inversion.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

SC063791

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel